3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
24
Endocrine
24
Thoracic
6
Gynecologic
6
Gastrointestinal
3
CNS
3
Plasma cell
2
Other hematologic neoplasm
2
NET
2
Myeloid
2
Dermatologic
2
Sarcoma
1
Lymphoid
1
Genitourinary
1
Breast
1
Conditions
Myelodysplastic Syndromes
361
Leukemia, Myeloid, Acute
302
Myeloproliferative Disorders
155
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
142
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Primary Myelofibrosis
103
Leukemia, Myelomonocytic, Chronic
89
Lymphoma, Non-Hodgkin
76
Leukemia
71
Polycythemia Vera
64
Multiple Myeloma
55
Hodgkin Disease
50
Hematologic Neoplasms
49
Leukemia, Lymphocytic, Chronic, B-Cell
44
Leukemia, Biphenotypic, Acute
41
Thrombocythemia, Essential
40
Lymphoma
40
Myelodysplastic-Myeloproliferative Diseases
32
Neoplasms
29
Leukemia, Myeloid, Chronic-Phase
28
Anemia, Refractory, with Excess of Blasts
24
Recurrence
23
Anemia, Aplastic
21
Lymphoma, Mantle-Cell
20
Lymphoma, Follicular
20
Hematologic Diseases
20
Burkitt Lymphoma
20
Blastic Plasmacytoid Dendritic Cell Neoplasm
20
Blast Crisis
20
Histiocytosis, Langerhans-Cell
19
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
Myeloid
×
1 year
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled